C-JWVPImmunis
stem cell-derived secretome, multi-active biologics, regenerative factors
modulatingbiologic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-JWVP
C-JWVPC-JWVPstem cell-derived secretome, multi-active biologics, regenerative factors
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Immunis stem cell-derived secretome, multi-active biologics, regenerative factors
Immunis is a private clinical-stage biotech in Irvine, California developing stem cell-derived secretome biologics for age-related muscle, metabolic, and immune-related dysfunction. Its lead program, IMM01-STEM, is presented as a multi-active regenerative and immune-modulating biologic for sarcopenia and sarcopenic obesity, with company-reported preliminary Phase 2 data in 47 obese seniors showing improved gait speed versus placebo, but the evidence is still mostly self-authored, interim, and not supported here by peer-reviewed clinical datasets or detailed trial reporting.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Immunis — Translational · Bottom quartile. Derived deterministically from 7 extracted project(s). Most-advanced status: phase 2. Band: translational. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic